David Risinger
Stock Analyst at Leerink Partners
(3.71)
# 809
Out of 4,667 analysts
165
Total ratings
65.12%
Success rate
17.35%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $57.93 | +26.03% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $45.16 | +52.81% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $4.66 | +243.35% | 1 | Oct 24, 2024 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Market Perform | $1,175 → $1,077 | $745.19 | +44.53% | 7 | Sep 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $20.28 | +116.96% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $86.98 | +75.90% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.85 | +1.52% | 3 | Aug 6, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.81 | +10.50% | 2 | Jul 9, 2024 | |
| ANAB AnaptysBio | Initiates: Outperform | $47 | $20.84 | +125.53% | 1 | Apr 16, 2024 | |
| AMGN Amgen | Upgrades: Outperform | $267 → $318 | $289.12 | +9.99% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $16.84 | -34.66% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $740.58 | -38.16% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $44.89 | -6.44% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $135 → $153 | $170.03 | -10.01% | 6 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $447.85 | -18.50% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $88.86 | +2.41% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.88 | +92.90% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $194 → $186 | $154.31 | +20.54% | 2 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.74 | -14.82% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $19.18 | -47.86% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $14.88 | +148.66% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $122.32 | +43.89% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $13.20 | +21.21% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $27.01 | +66.60% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $8.21 | +326.57% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $13.37 | +206.77% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $176.01 | -1.14% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $26.55 | +92.13% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $17.03 | -53.02% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $98.20 | -9.36% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $8.33 | -63.99% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $27.59 | -42.01% | 9 | Apr 2, 2020 |
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $57.93
Upside: +26.03%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $45.16
Upside: +52.81%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $4.66
Upside: +243.35%
Regeneron Pharmaceuticals
Sep 24, 2024
Downgrades: Market Perform
Price Target: $1,175 → $1,077
Current: $745.19
Upside: +44.53%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $20.28
Upside: +116.96%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $86.98
Upside: +75.90%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.85
Upside: +1.52%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.81
Upside: +10.50%
AnaptysBio
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $20.84
Upside: +125.53%
Amgen
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $289.12
Upside: +9.99%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $16.84
Upside: -34.66%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $740.58
Upside: -38.16%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $44.89
Upside: -6.44%
Feb 10, 2023
Upgrades: Market Perform
Price Target: $135 → $153
Current: $170.03
Upside: -10.01%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $447.85
Upside: -18.50%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $88.86
Upside: +2.41%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.88
Upside: +92.90%
Jan 20, 2023
Maintains: Outperform
Price Target: $194 → $186
Current: $154.31
Upside: +20.54%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.74
Upside: -14.82%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $19.18
Upside: -47.86%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $14.88
Upside: +148.66%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $122.32
Upside: +43.89%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $13.20
Upside: +21.21%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $27.01
Upside: +66.60%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $8.21
Upside: +326.57%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $13.37
Upside: +206.77%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $176.01
Upside: -1.14%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $26.55
Upside: +92.13%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $17.03
Upside: -53.02%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $98.20
Upside: -9.36%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $8.33
Upside: -63.99%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $27.59
Upside: -42.01%